Merge Healthcare

  
Cedara I-Response from Merge Healthcare 
Merge Healthcare (Booth 4058) is demonstrating the capabilities of its Cedara I-Response, an application designed to support clinical trial workflow and oncology viewing.

Cedara I-Response supports key concepts of double-blind reading, registration, advanced segmentation, comparison of multiple time points and support for clinical trial rules and has three distinct analysis techniques.  

The base Lesion Analysis package streamlines the clinical trials workflow of creating/exporting the RECIST, WHO and Volume measurements.  The PET/CT Analysis package enables users to compare standardized uptake values (SUV) over multiple time points.  The Functional Diffusion Mapping (fDM) Analysis package can track changes in tumors at the metabolic or cellular level over multiple time points. The fDM tool is a patented MR tumor analysis technique.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.